1. Home
  2. KIM vs ILMN Comparison

KIM vs ILMN Comparison

Compare KIM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KIM
  • ILMN
  • Stock Information
  • Founded
  • KIM 1958
  • ILMN 1998
  • Country
  • KIM United States
  • ILMN United States
  • Employees
  • KIM N/A
  • ILMN N/A
  • Industry
  • KIM Real Estate Investment Trusts
  • ILMN Medical Specialities
  • Sector
  • KIM Real Estate
  • ILMN Health Care
  • Exchange
  • KIM Nasdaq
  • ILMN Nasdaq
  • Market Cap
  • KIM 14.1B
  • ILMN 15.3B
  • IPO Year
  • KIM 1991
  • ILMN 2000
  • Fundamental
  • Price
  • KIM $21.88
  • ILMN $95.43
  • Analyst Decision
  • KIM Buy
  • ILMN Buy
  • Analyst Count
  • KIM 12
  • ILMN 15
  • Target Price
  • KIM $24.92
  • ILMN $124.27
  • AVG Volume (30 Days)
  • KIM 3.9M
  • ILMN 1.6M
  • Earning Date
  • KIM 10-30-2025
  • ILMN 10-30-2025
  • Dividend Yield
  • KIM 4.58%
  • ILMN N/A
  • EPS Growth
  • KIM 56.53
  • ILMN N/A
  • EPS
  • KIM 0.82
  • ILMN 7.91
  • Revenue
  • KIM $2,094,828,000.00
  • ILMN $4,284,000,000.00
  • Revenue This Year
  • KIM $4.66
  • ILMN N/A
  • Revenue Next Year
  • KIM $3.28
  • ILMN $2.74
  • P/E Ratio
  • KIM $26.54
  • ILMN $12.06
  • Revenue Growth
  • KIM 10.16
  • ILMN N/A
  • 52 Week Low
  • KIM $17.93
  • ILMN $68.70
  • 52 Week High
  • KIM $25.83
  • ILMN $156.66
  • Technical
  • Relative Strength Index (RSI)
  • KIM 55.33
  • ILMN 47.76
  • Support Level
  • KIM $20.75
  • ILMN $88.00
  • Resistance Level
  • KIM $21.41
  • ILMN $98.70
  • Average True Range (ATR)
  • KIM 0.37
  • ILMN 4.18
  • MACD
  • KIM 0.05
  • ILMN -0.25
  • Stochastic Oscillator
  • KIM 97.40
  • ILMN 49.53

About KIM Kimco Realty Corporation (HC)

One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: